person · Reporting owner

PERRY MARK L

Disclosed activity across 4 companies

Tapewire entity: 11385
SEC CIK: 0001190270

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GILEAD SCIENCES, INC.GILD · Entity 405	EVP Operations	February 03, 2004	February 04, 2004

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GILEAD SCIENCES, INC.

Report date February 03, 2004 · Filed February 04, 2004

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	203,772	Reported balance After 2004-02-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2004-02-03 · Exercise / conversion · Acquired 9,716 · Balance 203,772
Common StockSEC Table I · non-derivative	Direct	243,772	Reported balance After 2004-02-03 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2004-02-03 · Exercise / conversion · Acquired 40,000 · Balance 243,772
Common StockSEC Table I · non-derivative	Direct	246,056	Reported balance After 2004-02-03 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2004-02-03 · Exercise / conversion · Acquired 2,284 · Balance 246,056
Common StockSEC Table I · non-derivative	Direct	238,556	Reported balance After 2004-02-03 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2004-02-03 · Sale · Disposed 7,500 · Balance 238,556
Common StockSEC Table I · non-derivative	Direct	226,056	Reported balance After 2004-02-03 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2004-02-03 · Sale · Disposed 12,500 · Balance 226,056
Common StockSEC Table I · non-derivative	Direct	211,056	Reported balance After 2004-02-03 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2004-02-03 · Sale · Disposed 15,000 · Balance 211,056
Common StockSEC Table I · non-derivative	Direct	206,056	Reported balance After 2004-02-03 transaction · row 7 Account or security details depend on footnotes; rows are not merged. 1 source row Row 7 · 2004-02-03 · Sale · Disposed 5,000 · Balance 206,056
Common StockSEC Table I · non-derivative	Direct	201,056	Reported balance After 2004-02-03 transaction · row 8 Account or security details depend on footnotes; rows are not merged. 1 source row Row 8 · 2004-02-03 · Sale · Disposed 5,000 · Balance 201,056
Common StockSEC Table I · non-derivative	Direct	196,340	Reported balance After 2004-02-03 transaction · row 9 Account or security details depend on footnotes; rows are not merged. 1 source row Row 9 · 2004-02-03 · Sale · Disposed 4,716 · Balance 196,340
Common StockSEC Table I · non-derivative	Direct	196,040	Reported balance After 2004-02-03 transaction · row 10 Account or security details depend on footnotes; rows are not merged. 1 source row Row 10 · 2004-02-03 · Gift · Disposed 300 · Balance 196,040 F1: Represents transfer of shares to son under Uniform Gift to Minors Act. F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002.
Common StockSEC Table I · non-derivative	Indirectby Son	5,600	Reported balance After 2004-02-03 transaction · row 11 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 11 · 2004-02-03 · Gift · Acquired 300 · Balance 5,600 F1: Represents transfer of shares to son under Uniform Gift to Minors Act. F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002.
Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.59 · Expires 2009-07-22	Direct	4,568	Reported balance After 2004-02-03 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2004-02-03 · Exercise / conversion · Disposed 2,284 · Balance 4,568 F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.59 · Expires 2009-07-22	Direct	19,432	Reported balance After 2004-02-03 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2004-02-03 · Exercise / conversion · Disposed 9,716 · Balance 19,432 F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.81 · Expires 2010-04-05	Direct	53,252	Reported balance After 2004-02-03 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2004-02-03 · Exercise / conversion · Disposed 40,000 · Balance 53,252 F3: Options, split into incentive and non-qualified stock options, vest 20% on 4/05/2001, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 4/05/2005.

Filing footnotes · ownership attribution and instrument terms

F1: Represents transfer of shares to son under Uniform Gift to Minors Act.

F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004.

F3: Options, split into incentive and non-qualified stock options, vest 20% on 4/05/2001, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 4/05/2005.

F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-05 transaction · row 1 1 source row Row 1 · 2022-10-05 · Disposition to issuer · Disposed 37,865 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25	Direct	Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.30	Direct	Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 7,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75	Direct	Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09	Direct	Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30	Direct	Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

MyoKardia, Inc.

Report date November 17, 2020 · Filed November 19, 2020

Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-17 transaction · row 1 1 source row Row 1 · 2020-11-17 · Other · Disposed 29,508 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00	Direct	Reported balance After 2020-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-17 · Disposition to issuer · Disposed 21,800 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60	Direct	Reported balance After 2020-11-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00	Direct	Reported balance After 2020-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.85	Direct	Reported balance After 2020-11-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.77	Direct	Reported balance After 2020-11-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-17 · Disposition to issuer · Disposed 6,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.27	Direct	Reported balance After 2020-11-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-17 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

NVIDIA CORP

Report date June 26, 2024 · Filed June 26, 2024

Section 16 reporting ended · disclosed 2024-06-26. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 24, 2017 Filed May 26, 2017 21:02 UTC	NVIDIA CORP NVDA · Entity 1023	GrantCommon Stock	2,058	$0.00	$0.00	Disclosure SEC source: 0001045810-17-000093 · wf-form4_149583251997094.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,350 F2 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 15, 2017 and 50% of the shares on May 16, 2018. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document
March 06, 2017 Filed May 26, 2017 21:02 UTC	NVIDIA CORP NVDA · Entity 1023	GiftCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001045810-17-000093 · wf-form4_149583251997094.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,000 F1 · ownership.nature: Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees Read SEC document
July 13, 2016 Filed Jul 15, 2016 20:41 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionDirector Stock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $17.78	$0.00	Disclosure SEC source: 0001045810-16-000286 · wf-form4_146861527567716.xml · derivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document
July 13, 2016 Filed Jul 15, 2016 20:41 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	35,000	$52.93	$1,852,462.50	Disclosure SEC source: 0001045810-16-000286 · wf-form4_146861527567716.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,292 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $52.735 to $53.155. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
July 13, 2016 Filed Jul 15, 2016 20:41 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionCommon Stock	35,000	$17.78	$622,300.00	Disclosure SEC source: 0001045810-16-000286 · wf-form4_146861527567716.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 19, 2016 Filed May 23, 2016 20:06 UTC	NVIDIA CORP NVDA · Entity 1023	GrantCommon Stock	6,213	$0.00	$0.00	Disclosure SEC source: 0001045810-16-000265 · wf-form4_146403398312275.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,292 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 16, 2016 and 50% of the shares on May 17, 2017. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document
November 12, 2015 Filed Nov 16, 2015 21:38 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionDirector Stock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $12.46	$0.00	Disclosure SEC source: 0001045810-15-000169 · wf-form4_144770992938952.xml · derivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2016-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document
November 12, 2015 Filed Nov 16, 2015 21:38 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	40,000	$30.49	$1,219,704.00	Disclosure SEC source: 0001045810-15-000169 · wf-form4_144770992938952.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,079 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $30.365 to $30.64. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
November 12, 2015 Filed Nov 16, 2015 21:38 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionCommon Stock	40,000	$12.46	$498,400.00	Disclosure SEC source: 0001045810-15-000169 · wf-form4_144770992938952.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 21, 2015 Filed May 26, 2015 20:10 UTC	NVIDIA CORP NVDA · Entity 1023	GrantCommon Stock	10,283	$0.00	$0.00	Disclosure SEC source: 0001045810-15-000113 · wf-form4_143267101923679.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,079 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 18, 2015 and 50% of the shares on May 18, 2016. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document
February 18, 2015 Filed Feb 18, 2015 21:29 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionDirector Stock Option (Right to Buy) · Derivative	48,000	$0.00 Strike: $9.67	$0.00	Disclosure SEC source: 0001045810-15-000017 · wf-form4_142429496726068.xml · derivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,000 shares Expires 2015-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document
February 18, 2015 Filed Feb 18, 2015 21:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	48,000	$22.20	$1,065,499.20	Disclosure SEC source: 0001045810-15-000017 · wf-form4_142429496726068.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,796 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $22.155 to $22.24. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 18, 2015 Filed Feb 18, 2015 21:29 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionCommon Stock	48,000	$9.67	$464,160.00	Disclosure SEC source: 0001045810-15-000017 · wf-form4_142429496726068.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 27, 2014 Filed May 28, 2014 22:25 UTC	NVIDIA CORP NVDA · Entity 1023	GrantCommon Stock	12,208	$0.00	$0.00	Disclosure SEC source: 0001045810-14-000107 · wf-form4_140131592865931.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,796 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 19, 2014 and 50% of the shares on May 20, 2015. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document
May 16, 2013 Filed May 20, 2013 23:46 UTC	NVIDIA CORP NVDA · Entity 1023	GrantCommon Stock	17,307	$0.00	$0.00	Disclosure SEC source: 0001045810-13-000042 · wf-form4_136909355490225.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,307 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 20, 2013 and 50% of the shares on May 21, 2014. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document
May 18, 2012 Filed May 23, 2012 00:52 UTC	NVIDIA CORP NVDA · Entity 1023	GrantCommon Stock	16,281	$0.00	$0.00	Disclosure SEC source: 0001209191-12-029865 · doc4.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,281 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 21, 2012 and 50% of the shares on May 15, 2013. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document
May 19, 2011 Filed May 23, 2011 23:37 UTC	NVIDIA CORP NVDA · Entity 1023	GrantDirector Stock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $17.78	$0.00	Disclosure SEC source: 0001209191-11-030573 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2021-05-18 F1 · derivative.exercise_date: Annual grant in connection with service on the Board of Directors. The grant shall vest quarterly over one year, commencing on May 19, 2011. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested and exercisable. Read SEC document
April 06, 2011 Filed Apr 8, 2011 22:49 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionDirector Stock Option (Right to Buy) · Derivative	175,000	Not disclosed Strike: $8.47	Not disclosed	Disclosure SEC source: 0001209191-11-022404 · doc4.xml · derivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2011-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Inapplicable. F2 · derivative.exercise_date: Fully vested. Read SEC document
April 06, 2011 Filed Apr 8, 2011 22:49 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	175,000	$17.41	$3,046,330.00	Disclosure SEC source: 0001209191-11-022404 · doc4.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $17.315 to $17.54. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
April 06, 2011 Filed Apr 8, 2011 22:49 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionCommon Stock	175,000	$8.47	$1,482,250.00	Disclosure SEC source: 0001209191-11-022404 · doc4.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 20, 2010 Filed May 20, 2010 22:35 UTC	NVIDIA CORP NVDA · Entity 1023	GrantDirector Stock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $12.46	$0.00	Disclosure SEC source: 0001209191-10-029445 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2016-05-19 F1 · derivative.exercise_date: Automatic grant in connection with service on the Board of Directors. The grant shall vest quarterly over one year, commencing on May 20, 2010. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested and exercisable. Read SEC document
May 21, 2009 Filed May 26, 2009 20:48 UTC	NVIDIA CORP NVDA · Entity 1023	GrantDirector Stock Option (Right to Buy) · Derivative	48,000	$0.00 Strike: $9.67	$0.00	Disclosure SEC source: 0001209191-09-028758 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2015-05-20 F1 · derivative.exercise_date: Automatic grant in connection with service on the Board of Directors. The grant shall vest quarterly over one year, commencing on May 21, 2009. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested and exercisable. Read SEC document
June 20, 2008 Filed Jun 24, 2008 22:24 UTC	NVIDIA CORP NVDA · Entity 1023	GrantDirector Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $19.76	$0.00	Disclosure SEC source: 0001209191-08-038678 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2014-06-19 F2 · derivative.exercise_date: Automatic grant in connection with service on a Committee of the Board of Directors. The grant shall vest on the first anniversary of the grant date, provided that the Reporting Person has attended at least 75% of the Committee meetings in the year following the grant date. If the Reporting Person has attended fewer than 75% of the Committee meetings in the year following the grant date, the grant shall vest 10% per year for each of the first three years after the grant, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the first anniversary of the grant date due to disability, the grant shall immediately vest and become exercisable on a monthly pro rata basis. If the Reporting Person's service as a director terminates due to death, the grant shall immediately vest and become exercisable. Read SEC document
June 20, 2008 Filed Jun 24, 2008 22:24 UTC	NVIDIA CORP NVDA · Entity 1023	GrantDirector Stock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $19.76	$0.00	Disclosure SEC source: 0001209191-08-038678 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2014-06-19 F1 · derivative.exercise_date: Automatic grant in connection with service on the Board of Directors. The grant shall begin vesting on the second anniversary of the grant date and thereafter shall vest quarterly over one year, being fully vested in 2011, provided that the Reporting Person has attended at least 75% of the Board of Directors meetings in the two year period following the grant date. If the Reporting Person has not attended at least 75% of the Board of Directors meetings in the two year period following the grant date, the grant shall vest 30% on the third anniversary of the grant date, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the second anniversary of the grant date due to disability, the grant shall immediately vest and become exercisable on a quarterly pro rata basis. If the Reporting Person's service as a director terminates due to death, the grant shall immediately vest and become exercisable. Read SEC document
January 18, 2008 Filed Jan 23, 2008 18:10 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionDirector Stock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $8.47	$0.00	Disclosure SEC source: 0001243233-08-000012 · edgar.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 50,000 shares Expires 2011-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The option was previously reported as covering 75,000 shares at an exercise price of $25.42, but was adjusted to reflect the stock splits that occurred on April 6, 2006 and September 10, 2007. F3 · derivative.exercise_date: The option vests quarterly over a three year period beginning May 17, 2005. Read SEC document
January 18, 2008 Filed Jan 23, 2008 18:10 UTC	NVIDIA CORP NVDA · Entity 1023	Exercise / conversionCommon Stock	50,000	$8.47	$423,500.00	Disclosure SEC source: 0001243233-08-000012 · edgar.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the 3-for-2 stock split of the Company's Common Stock on September 10, 2007. Read SEC document
June 22, 2007 Filed Jun 26, 2007 22:39 UTC	NVIDIA CORP NVDA · Entity 1023	GrantDirector Stock Option (Right to Buy) · Derivative	8,000	$0.00 Strike: $43.62	$0.00	Disclosure SEC source: 0001243233-07-000012 · edgar.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2013-06-21 F2 · derivative.exercise_date: Automatic grant in connection with service on a Committee of the Board of Directors. The grant shall vest on the first anniversary of the grant date, provided that the Reporting Person has attended at least 75% of the Committee meetings in the year following the grant date. If the Reporting Person has attended fewer than 75% of the Committee meetings in the year following the grant date, the grant shall vest 10% per year for each of the first three years after the grant, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the first anniversary of the grant date due to disability, the grant shall immediately vest and become exercisable on a monthly pro rata basis. If the Reporting Person's service as a director terminates due to death, the grant shall immediately vest and become exercisable. Read SEC document
June 22, 2007 Filed Jun 26, 2007 22:39 UTC	NVIDIA CORP NVDA · Entity 1023	GrantDirector Stock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $43.62	$0.00	Disclosure SEC source: 0001243233-07-000012 · edgar.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2013-06-21 F1 · derivative.exercise_date: Automatic grant in connection with service on the Board of Directors. The grant shall begin vesting on the second anniversary of the grant date and thereafter shall vest quarterly over one year, being fully vested in 2010, provided that the Reporting Person has attended at least 75% of the Board of Directors meetings in the two year period following the grant date. If the Reporting Person has not attended at least 75% of the Board of Directors meetings in the two year period following the grant date, the grant shall vest 30% on the third anniversary of the grant date, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the second anniversary of the grant date due to disability, the grant shall immediately vest and become exercisable on a quarterly pro rata basis. If the Reporting Person's service as a director terminates due to death, the grant shall immediately vest and become exercisable. Read SEC document
August 01, 2006 Filed Aug 3, 2006 22:46 UTC	NVIDIA CORP NVDA · Entity 1023	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $22.14	$0.00	Disclosure SEC source: 0001190270-06-000002 · edgar.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2012-07-31 F2 · derivative.exercise_date: Automatic grant in connection with service on a Committee of the Board of Directors. The grant shall vest on the first anniversary of the grant date, provided that the Reporting Person has attended at least 75% of the Committee meetings in the year following the grant date. If the Reporting Person has attended fewer than 75% of the Committee meetings in the year following the grant date, the grant shall vest 10% per year for each of the first three years after the grant, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the first anniversary of the grant date due to disability or death, the grant shall immediately vest and become exercisable on a monthly pro rata basis. Read SEC document
August 01, 2006 Filed Aug 3, 2006 22:46 UTC	NVIDIA CORP NVDA · Entity 1023	GrantNon-Qualified Stock Option (right to buy) · Derivative	30,000	$0.00 Strike: $22.14	$0.00	Disclosure SEC source: 0001190270-06-000002 · edgar.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2012-07-31 F1 · derivative.exercise_date: Automatic grant in connection with service on the Board of Directors. The grant shall begin vesting on the second anniversary of the grant date and thereafter shall vest quarterly over one year, being fully vested in 2009, provided that the Reporting Person has attended at least 75% of the Board of Directors meetings in the two year period following the grant date. If the Reporting Person has not attended at least 75% of the Board of Directors meetings in the two year period following the grant date, the grant shall vest 30% on the third anniversary of the grant date, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the second anniversary of the grant date due to disability or death, the grant shall immediately vest and become exercisable on a quarterly pro rata basis. Read SEC document
May 17, 2005 Filed May 19, 2005 22:39 UTC	NVIDIA CORP NVDA · Entity 1023	GrantDirector stock option (Right to buy) · Derivative	75,000	$0.00 Strike: $25.42	$0.00	Disclosure SEC source: 0001190270-05-000005 · edgar.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2011-05-16 F1 · derivative.exercise_date: Non-discretionary grant under NVIDIA's 1998 Non-Employee Directors' Stock Option Plan in connection with the Reporting Person joining the Board of Directors. The option vests quarterly over a three year period beginning May 17, 2005. Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	40,000	$0.00 Strike: $14.81	$0.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · derivative · entry 14 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,252 Underlying: Common Stock · 40,000 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options, split into incentive and non-qualified stock options, vest 20% on 4/05/2001, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 4/05/2005. Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,716	$0.00 Strike: $14.59	$0.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · derivative · entry 13 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,432 Underlying: Common Stock · 9,716 shares Expires 2009-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004. Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	2,284	$0.00 Strike: $14.59	$0.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · derivative · entry 12 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,568 Underlying: Common Stock · 2,284 shares Expires 2009-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004. Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	300	$0.00	$0.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 11 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by Son Disclosed balance after: 5,600 F1 · kind: Represents transfer of shares to son under Uniform Gift to Minors Act. F4 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	300	$0.00	$0.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 10 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,040 F1 · kind: Represents transfer of shares to son under Uniform Gift to Minors Act. F4 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	4,716	$56.79	$267,821.64	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 9 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,340 Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	5,000	$56.75	$283,750.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 8 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,056 Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	5,000	$56.60	$283,000.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 7 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,056 Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	15,000	$56.57	$848,550.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 6 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,056 Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	12,500	$56.55	$706,875.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 5 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,056 Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	7,500	$56.50	$423,750.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 4 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,556 Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	2,284	$14.59	$33,332.24	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 3 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	40,000	$14.81	$592,500.00	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 03, 2004 Filed Feb 4, 2004 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	9,716	$14.59	$141,793.36	Disclosure SEC source: 0001179110-04-002469 · edgar.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 28, 2004 Filed Jan 30, 2004 22:43 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Option (right to buy) · Derivative	123,363	$0.00 Strike: $61.06	$0.00	Disclosure SEC source: 0001179110-04-002095 · edgar.xml · derivative · entry 4 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,363 Underlying: Common Stock · 123,363 shares Expires 2014-01-28 F2 · derivative.exercise_date: Options (split between incentive and non qualified stock options) vest 20% on the first anniversary date of the grant, and the remaining balance will vest quarterly over a four year period beginning on 1/28/05. The option will be fully vested by 1/28/09. Read SEC document
January 28, 2004 Filed Jan 30, 2004 22:43 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantIncentive Stock Option (right to buy) · Derivative	1,637	$0.00 Strike: $61.06	$0.00	Disclosure SEC source: 0001179110-04-002095 · edgar.xml · derivative · entry 3 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,637 Underlying: Common Stock · 1,637 shares Expires 2014-01-28 F2 · derivative.exercise_date: Options (split between incentive and non qualified stock options) vest 20% on the first anniversary date of the grant, and the remaining balance will vest quarterly over a four year period beginning on 1/28/05. The option will be fully vested by 1/28/09. Read SEC document
October 31, 2003 Filed Nov 4, 2003 01:09 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative	44,000	$0.00 Strike: $14.59	$0.00	Disclosure SEC source: 0001179110-03-009848 · edgar.xml · derivative · entry 8 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,148 Underlying: Common Stock · 44,000 shares Expires 2009-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest over a five year period beginning 07/22/2000, the first anniversary date of the grant. The options continue to vest in quarterly installments over the next four years, ending on July 22, 2004. Read SEC document
October 31, 2003 Filed Nov 4, 2003 01:09 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	4,000	$54.70	$218,800.00	Disclosure SEC source: 0001179110-03-009848 · edgar.xml · nonDerivative · entry 6 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,039 Read SEC document
October 31, 2003 Filed Nov 4, 2003 01:09 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	10,000	$54.60	$546,000.00	Disclosure SEC source: 0001179110-03-009848 · edgar.xml · nonDerivative · entry 5 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,039 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.